PL017 Inhibitor – Pl 017

Selective u opioid receptor agonist (IC50 values are 5.5 and > 10000nM for inhibition of 125I-FK 33,824 and 125I-DADLE binding to u and delta sites respectively). Produces naloxone-reversible analgesia, catalepsy and hyperthermia following central administration in rats in vivo.

Chang et al (1983) Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J.Pharmacol.Exp. Ther. 227 403 PMID:
Chang et al (1983) Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J.Pharmacol.Exp. Ther. 227 403 PMID:
Meyer and Meyer (1993) Behavioral effects of the mu-opioid peptide agonists DAMGO, DALDA and PL017 on locomotor activities. Pharmacol. Biochem. Behav. 46 391 PMID:
Meyer and Meyer (1993) Behavioral effects of the mu-opioid peptide agonists DAMGO, DALDA and PL017 on locomotor activities. Pharmacol. Biochem. Behav. 46 391 PMID:
Xin et al (1997) Body temperature and analgesic effects of selective mu and kappa opioid receptor agonists microdialyzed into rat brain. J.Pharmacol.Exp. Ther. 281 499 PMID:
Xin et al (1997) Body temperature and analgesic effects of selective mu and kappa opioid receptor agonists microdialyzed into rat brain. J.Pharmacol.Exp. Ther. 281 499 PMID:

Small volumes of PL017, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5763956 is an inhibitor targeting PL017. Also known as PL 017.